Search PubMed⌕ Search

Biomedical subjects

T Russo

Publications and source records attributed to T Russo.

At least 73 records · Page 4Linked to original sources
PubMed1988

Oligonucleotide-directed mutagenesis: a sequence-based screening.

A procedure to screen for mutant clones obtained by oligonucleotide-directed mutagenesis has been developed. It is based on the preparation of phage containing supernatants from a number (100 or more) of randomly chosen mutagenized M13 plaques. Aliquots from these supernatants are mixed to obtain pools, each containing 10 phages. Heterogeneous single-stranded DNA is prepared from these pools and used as template in a "single letter" sequence according to the dideoxy chain terminator method. Thus, the pool(s) containing the mutated sequence and the mutated sequence itself is identified by sequencing the single-stranded DNAs of the 10 phages present in the selected pool.

Animals↗
PubMed1988

Postfusional latency in stereoscopic slant perception and the primitives of stereopsis.

Random dot stereograms of slanted surfaces were constructed, each representing one or two slanted surfaces in different relative arrangements and with different axes. Latency to fusion and from fusion to stereoscopic resolution was measured for each stimulus. It was found that latency to fusion was always very brief but that latency to stereoscopic resolution varied markedly, depending upon the orientation and arrangement of the stereoscopic surfaces. A gradient of discontinuities at a surface boundary produced an instant slant response for that surface, whereas a gradient of absolute disparities across the surface did not, except under conditions where vertical declination (a form of orientation disparity) was present. We conclude that stereopsis is not based on the primitives used in matching the images for fusion and that it is, at least initially, a response to disparity discontinuities which play no role in the fusion process. We also conclude that vertical declination is responded to globally as a slant around a horizontal axis but that other forms of orientation disparity are ineffective. The evidence from our experiments does not support the existence of a stereoscopic ability to respond globally to differences in magnification (or spatial frequency). It is suggested that stereoscopic perception of slant around a vertical axis is slow because it results from the integration of local processes.

Attention↗
PubMed1987

The transcriptional efficiency of clustered tRNA genes is affected by their position within the cluster.

The transcription of a mouse genomic segment containing four tRNA genes, coding for a tRNA(Ala), a tRNA(Ile), a tRNA(Pro) and a tRNA(Lys), has been studied in a HeLa cell extract, demonstrating that differences among their transcriptional efficiencies are evident using as templates either the natural cluster or an equimolecular mixture of the four isolated genes. Nevertheless, the structure of the cluster influences the transcriptional efficiency of the clustered genes. In fact, a cis-acting inhibitory sequence has been located at about 400 bp downstream of the tRNA(Pro) coding sequence. Moreover rearrangements of the reciprocal position of the various tRNA genes within the cluster results in significant changes in the transcriptional rates of the individual transcriptional units.

Animals↗
PubMed1986

Structure and in vitro transcription of tRNA gene clusters containing the primers of MuLV reverse transcriptase.

Three genes coding for mouse tRNAPro have been isolated from a genomic library and characterized both structurally and functionally. Two of these (tPro52 and tPro53) code for the tRNA primer of reverse transcriptase of MuLV. The third one (tPro51) shows several differences (mutations and deletions) that probably prevent the folding of the matured transcript into the cloverleaf structure, and is therefore a pseudogene. This pseudogene gives rise to a RNA transcription product in vitro. tPro52 is clustered with a tRNALys gene and with a tRNAAla gene, which is strongly homologous to the rat identifier repeated sequence. tPro53 is clustered with a tRNAAsp and a tRNAGly gene. Other tRNA-hybridizing sequences are present in the lambda clones that contain tPro51 and tPro53.

Anticodon↗
PubMed1985

A microcomputer program for the identification of tRNA genes.

A microcomputer program which locates tRNA genes within long DNA sequences is described. The search is performed either by identifying tRNA-like secondary structures or by locating eukaryotic RNA polymerase III promoter consensus sequences. The program is also useful in finding inverted repeats allowing the formation of stem-loop secondary structures in tRNA. The program has been developed in BASIC and 6502 Assembler and runs on the Apple II plus and IIe microcomputers. The execution is quite fast; all the operations are carried out in 1-90 s, depending on the required task and on the sequence length.

Base Sequence↗
PubMed1985

Pseudouridine excretion and transfer RNA primers for reverse transcriptase in tumors of retroviral origin.

To evaluate the relationship between pseudouridine increase in biological fluids and retroviral cell transformation, we have studied the effect of retrovirus infection and/or transformation on the rate of pseudouridine excretion by chick embryo fibroblasts. The results show that: pseudouridine excretion by chick embryo fibroblasts transformed by Rous sarcoma virus is several times higher than that of normal cells; this increased excretion precedes by many hours the appearance of the morphological signs of transformation and it is always present when neosynthesized infectious viral particles are released into the culture medium; and pseudouridine excretion was also increased in cells infected by a mutant of Rous sarcoma virus (RAV-1) which, lacking the src gene, does not transform the cells but replicates normally. To investigate if pseudouridine overproduction is related to an altered turnover rate of specific transfer RNA (tRNA) species which functions as primer of retrovirus reverse transcriptase, the concentration of non-acylated proline-accepting tRNA and non-acylated tryptophan-accepting tRNA, primers of reverse transcriptase of murine leukemia virus and of Rous sarcoma virus, respectively, has been measured, the former in normal and transformed AKR thymus and the latter in normal fibroblasts and in fibroblasts infected by Rous sarcoma virus or by its nontransforming mutant. The results show that in both systems a significant increase of the primer tRNA species occurs in the infected or transformed cells.

Animals↗
PubMed1984

Determination of pseudouridine in tRNA and in acid-soluble tissue extracts by high-performance liquid chromatography.

A high-performance liquid chromatographic method to measure pseudouridine and other nucleosides in hydrolyzed unfractionated tRNA and in acid soluble tissue extracts is described. The method is based on the following steps: tRNA extraction and hydrolysis by a mixture of ribonuclease A, snake venom phosphodiesterase and bacterial alkaline phosphatase; nucleoside purification (in the case of acid soluble tissue extract) by affinity chromatography on a phenyl-boronate gel column; nucleoside separation and quantitation by high-performance liquid chromatography on an octadecylsilane column by a reversed polarity gradient elution. The procedure allows a very accurate quantitation of pseudouridine and some other nucleosides, and its sensitivity is such that only 20 micrograms of tRNA are required. The method has been utilized to compare the pseudouridine content of hydrolyzed tRNA extracted from normal and lymphomatous murine thymus, as well as the pseudouridine content in acid soluble extracts from the same tissues.

Animals↗
PubMed1984

Serum pseudouridine as a biochemical marker in the development of AKR mouse lymphoma.

Pseudouridine is a modified nucleoside derived from the degradation of some species of RNA, primarily transfer RNA, the level of which is elevated in biological fluids of tumor-bearing subjects. In order to study the relationship between pseudouridine levels and the development and progression of neoplasia, we have measured pseudouridine levels in the serum of inbred mice with high (AKR) and low (BALB/c) incidence of spontaneous lymphoma and in mice carrying transplantable lymphoid tumors. Our results show that the serum level of pseudouridine: (a) in healthy mice, is higher in females than in males; (b) increases significantly in female AKR mice in the period preceding the development of lymphoma (preneoplastic period occurring at about 6 months of age); and (c) is highest in AKR mice with lymphoma, the most elevated levels being found in mice with widely disseminated disease. The latter observation was confirmed by experiments with a transplantable AKR lymphoma (T2), where a positive correlation between tumor burden and serum pseudouridine levels was found. On the contrary, in BALB/c mice carrying a transplantable myeloma tumor (MOPC-460), no increase was seen despite the presence of a considerable tumor burden. The increase of pseudouridine in the preneoplastic period, in the absence of overt disease is viewed as an early sign of the development of the disease.

Animals↗
PubMed1983

Determination of pseudouridine and other nucleosides in human blood serum by high-performance liquid chromatography.

A specific, sensitive, and rapid method to measure pseudouridine in human blood serum is described. The method is based on the following steps: (i) deproteinization of serum samples by filtration on membrane cones or by acetonitrile; (ii) purification of nucleosides and concentration of the sample by affinity chromatography on phenylboronate gel followed by lyophilization; and (iii) separation of nucleosides and their quantitation by reverse-phase high-performance liquid chromatography. The pseudouridine mean value in 30 normal subjects was 2.52 +/- 0.28 nmol/ml. The procedure also allows the identification of inosine, uridine, guanosine, and adenosine. Nevertheless, the presence in human blood serum of enzymatic activities which convert adenosine to inosine and cytidine to uridine prevents the precise quantitation of these nucleosides. All the compounds were identified by comparing their retention times and absorbance ratios (A280/A254) with those of pure compounds, as well as by cochromatography.

Chromatography, High Pressure Liquid↗
PubMed1983

Modified nucleosides in body fluids of tumor-bearing patients.

The catabolism of nucleic acids, particularly tRNA, produces a variety of modified nucleosides which are not reutilized by mammalian cells. Investigation of these compounds in body fluids, mainly urine, has recently provided evidence of altered metabolic situations in tumor-bearing patients. The factors involved in the alterations of modified nucleosides formation are connected with altered tRNA-modifying enzymes and/or altered turnover of subpopulations of tRNA. A common pattern in tumor cells or tissues is the presence of isoaccepting tRNA species containing aberrant nucleoside modifications. Several modified nucleosides have been detected and quantitated by HPLC analysis of the urine of normal subjects and cancer patients. Results obtained, in the authors' laboratory, among others, indicate a possible correlation between urinary excretion of these compounds and the course of the disease, with implications for the follow-up of therapeutic treatment. Particular reference should be made to psi, which appears to be a suitable marker for monitoring these subjects. The data from the authors' laboratory also show that the analysis of modified nucleosides in blood may be considered a useful tool in the search for proper markers associated with the cancer status. In this respect psi is suggested as a biochemical indicator for cancer patients.

Chromatography, High Pressure Liquid↗
PubMed1983

Pseudouridine determination in blood serum as tumor marker.

A new method to measure pseudouridine (psi rd) in blood serum has been used to study patients with cancer of breast, lung, colon, and ovaries, and patients with hepatomas, non-Hodgkin lymphomas, and acute lymphoblastic leukemias, at different stages. The results indicate: (1) a significant (p less than 0.01) difference between the psi rd serum level of the cancer patient group and the normal control group; (2) that the increase of the level of serum psi rd is correlated both to the stage of the disease and to the spreading of the tumor tissue; (3) a correlation between the response to therapy and the behaviour of psi rd serum levels.

Breast Neoplasms↗